Extensive dabigatran-induced exfoliative esophagitis harboring squamous cell carcinoma

A 90-year-old woman presented to the emergency ward with chest pain and odynophagia. Her medical history included chronic atrial fibrillation, for which she had been started on a treatment with the novel oral anticoagulant dabigatran 6 months previously. The patient had not complied with the strict instructions relevant to the intake of dabigatran, namely that it needs to be taken while in an upright position with food or with an 8-ounce glass of water. After exclusion of myocardial infarction, an esophagogastroduodenoscopy (EGD, GIF H180, Olympus, Hamburg, Germany) was performed, and revealed extensive exfoliative esophagitis with spontaneously sloughed esophageal casts, findings that were most prominent in the distal part of the esophagus (Fig. 1). In addition, we observed an irregular nodular segment in the mid-esophagus. The patient was treated with proton pump inhibitors and was kept nil by mouth; dabigatran was discontinued.

A repeat EGD 3 days later showed marked improvement in the esophagitis with scarring and patchy residual erosions and erythema (Fig. 2a). However, 29–31 cm from the incisors, there was a semicircumferential polypoid mass that was highly suspicious of esophageal carcinoma (Fig. 2b), a diagnosis that was supported by the findings on narrow band imaging (Fig. 2c).

Histopathology of biopsies taken from this lesion confirmed the presence of a poorly differentiated squamous cell carcinoma, while mucosal biopsies displayed parakeratosis and acanthosis. Serology and direct immunofluorescence to exclude medication-induced pemphigoid were negative. The patient underwent an endoscopic ultrasound (EUS), which revealed a T2N+ lesion, and computed tomography (CT) excluded metastatic disease. Given her advanced age, the patient was referred for palliative radiotherapy. Dabigatran was permanently withdrawn.

Dabigatran is a novel oral anticoagulant which poses new challenges in terms of the management of any complicating gastrointestinal hemorrhage and because of its propensity to cause potentially severe esophagitis [1,2]. Although the important question as to mere coincidence or causal relationship must remain open, this is the first reported case of malignancy in the setting of severe dabigatran-related esophageal injury, illustrating that re-endoscopy after drug withdrawal appears to be a reasonable approach to ensure that other esophageal lesions do not go unnoticed [3].

Competing interests: None

Vincent Zimmer, Markus Casper, Frank Lammert
Department of Medicine II, Saarland University Hospital, Homburg, Germany
References

Bibliography
DOI http://dx.doi.org/10.1055/s-0034-1365782
Endoscopy 2014; 46: E273–E274
© Georg Thieme Verlag KG
Stuttgart · New York
ISSN 0013-726X

Corresponding author
Vincent Zimmer, MD
Department of Medicine II
Saarland University Hospital
Kirberger Str.
66421 Homburg
Germany
Fax: +49-6841-1621305
vincent.zimmer@uks.eu